MedTrace Logo

Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV

NCT05163834 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-03-17

No results posted yet for this study

Summary

This is a randomized, open-label, placebo-controlled phase 1 study in healthy adult volunteers to provide information regarding vaccination with a common pneumococcal polysaccharide vaccine while receiving efgartigimod.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

Efgartigimod

intravenous infusion of efgartigimod

OTHER

Placebo

intravenous infusion of placebo

BIOLOGICAL

PNEUMOVAX 23

PNEUMOVAX 23 vaccine

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-17
Primary Completion
2022-03-08
Completion
2022-03-08

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05163834 on ClinicalTrials.gov